Frank Charles Miranda, P.A. is currently reviewing claims from men who have suffered a heart attack, stroke, deep vein thrombosis (DVT), blood clots, pulmonary embolism or other injuries while taking testosterone supplements. These prescription products include Androderm, Androgel, Axiron, Bio-T-Gel, Striant and Testopel. These products have all been approved by the FDA and are applied through a transdermal patch, buccal swab, gel application or an injection.
Testosterone and the increased risk of heart attack or stroke:
In November 2013 the Journal of the American Medical Association (JAMA) published a study in which more than 8,000 male veterans with low testosterone were studied. Researchers compared the risk of cardiovascular illness for those who received testosterone supplements with the men who did not receive the supplements, and found that those who used supplements were 29% more likely to have a heart attack or a stroke after three years.
The role of the FDA and its evaluation of testosterone supplements:
The FDA announced in January 2014 that it would be evaluating the risk of stroke, heart attack and death from testosterone supplement products. In a safety alert, the agency explained that it would reassess the safety of testosterone therapy products.
Low testosterone products include but are not limited to:
- Androgel
- Androderm
- Axiron
- Bio-T-Gel
- Delatestryl
- Testim
- Testopel
Filing a claim for injuries caused by testosterone replacement therapy (TRT):
Contact our office today at 814.254.2637 to schedule a free legal consultation regarding any potential claim for injuries caused by testosterone replacement therapy (TRT). We look forward to working with you to resolve any injury claim.